Annual report pursuant to Section 13 and 15(d)

Note purchase agreement and consulting agreement with G FarmaLabs Limited (Details Narrative)

v3.22.1
Note purchase agreement and consulting agreement with G FarmaLabs Limited (Details Narrative) - USD ($)
 12 Months Ended
Aug. 27, 2021
Mar. 04, 2019
Mar. 17, 2017
Dec. 31, 2021
Dec. 31, 2020
Nov. 04, 2020
Apr. 22, 2019
Two promissory notes [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Debt Instrument, Face Amount           $ 1,166,570  
G FarmaLabs Limited [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Notes receivable bad debt reserve       $ 1,043,531 $ 1,045,051    
Notes receivable related party       0 $ 0    
Other income       $ 1,500      
G FarmaLabs Limited [Member] | Mentor partner I [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Cost of impounded assets             $ 427,804
Notes purchase agreement [Member] | G FarmaLabs Limited [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Debt Instrument, Face Amount   $ 990,000 $ 500,000        
Debt Instrument, Interest Rate, Stated Percentage     7.42%        
Debt Instrument, Maturity Date     Apr. 15, 2022        
Debt Instrument, Periodic Payment   $ 10,239          
Settlement agreement and mutual release [Member] | G Farma [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Liability for Unpaid Claims and Claims Adjustment Expense Schedule, Discussion The Settlement Agreement requires the G Farma Entities to pay the Company an aggregate of $            
Liability for Unpaid Claims and Claims Adjustment Expense, Net $ 500,000            
Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments $ 2,000,000            
Settlement agreement and mutual release [Member] | Mentor partner I [Member] | G Farma [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Liability for Unpaid Claims and Claims Adjustment Expense Schedule, Discussion The Settlement Agreement requires the G Farma Entities to pay the Company an aggregate of $500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5th thereafter, until the settlement amount and accrued unpaid interest are paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25% per annum, commencing February 25, 2021, compounded monthly, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1%.